Narwhal Capital Management’s Quest Diagnostics DGX Stock Holding History

Narwhal Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.83M	Buy	+13,348	New	+$2.62M	0.2%	75

Other funds holding DGX

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BCAM

Boston Common Asset Management Boston, Massachusetts $1.69B AUM 28.29% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Narwhal Capital Management's DGX Position: Q2 2026 in Review

Narwhal Capital Management opened a new position in Quest Diagnostics (DGX) in Q2 2026: 13,348 shares worth $2.83M. The stake represents 0.2% of the portfolio and ranks #75 among its holdings.

287 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Narwhal Capital Management held 13,348 shares of Quest Diagnostics worth $2.83M as of Q2 2026.
Quest Diagnostics was a new Narwhal Capital Management position in Q2 2026.
Quest Diagnostics made up 0.2% of Narwhal Capital Management's portfolio in Q2 2026, its #75 holding.
287 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Narwhal Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.